RAY SKWIERCZYNSKI, PHD

Head of technical operations

Dr. Raymond Skwierczynski is Head of Technical Operations at Tremeau Pharmaceuticals. He served in this capacity as a consultant prior to joining Tremeau fulltime in 2019.  His responsibilities include drug substance and drug product development, manufacturing, supply chain, CMC quality assurance, and CMC regulatory.

Previously, Dr. Skwierczynski was Head of Pharmaceutical Operations and a corporate officer at CoLucid Pharmaceuticals, a Phase 3 clinical-stage biopharmaceutical company that developed lasmiditan for the acute treatment of migraines.  CoLucid was acquired by Eli Lilly in 2017. 

Prior to CoLucid, Dr. Skwierczynski held various leadership positions at Takeda Pharmaceutical Company (formerly Millennium Pharmaceuticals), where he led departments responsible for preformulation, formulation, and analytical development of inflammation and oncology drugs.  He also led the late-stage CMC development of NINLARO® (ixazomib), an oral proteasome inhibitor for the treatment of multiple myeloma.  Earlier in his career, Dr. Skwierczynski held positions of increasing responsibility with 3M Pharmaceuticals, Roche Carolina, and Baxter.

He holds a BS degree from the University of Wisconsin-Eau Claire and MS and PhD degrees in Pharmaceutics from the University of Wisconsin.  He completed a PhRMA Foundation Post-doctoral Fellowship in the Chemistry Department also at the University of Wisconsin.  Dr. Skwierczynski serves as a member of an Expert Committee for the United States Pharmacopeia and on the Board of Directors for the University of Wisconsin-Eau Claire Foundation.  Previously, he served on the Board of Directors for Yankee Clipper Council, Boy Scouts of America.